INS and type 2 diabetes mellitus: Intriguingly, in ONWARDS 4, which focused on individuals with type 2 diabetes on a basal–bolus regimen, at the end of the study, while the total amount of insulin used was similar between the icodec and glargine U100 groups, participants in the icodec group received a significantly higher mean weekly basal insulin dose (305 vs 279 U) and a lower mean weekly bolus dose (197 vs 255 U) [33].